Agents for influenza neutralization
The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
1. A composition comprising an engineered antibody that:
(a) has a heavy chain variable region that shows at least 99% substantial sequence homology with that of heavy chain variable region of SEQ ID NO: 1; and
(b) has a light chain variable region that shows at least 99% substantial sequence homology to one of SEQ ID NOs: 33-43.
2. A cell line expressing the engineered antibody of claim 1 .
3. The cell line of claim 2 , wherein the cell line is a mammalian cell line.
4. The cell line of claim 2 , wherein the cell line is a hybridoma.
5. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient.
6. A kit comprising:
the composition of claim 1 ;
a syringe, needle, or applicator for administration of the antibody to subject;
and instructions for use.
7. A method of treating a subject, the method comprising steps of: administering to a subject suffering from or susceptible to influenza infection therapeutically effective amount of an antibody agent that:
(a) has a heavy chain variable region that:
(i) shows at least 99% substantial sequence homology with that of heavy chain variable region of SEQ ID NO: 1; and
(ii) shares at least one CDR with SEQ ID NO: 1; and
(b) has a light chain variable region that shows at least 99% substantial sequence homology to one of SEQ ID NOs: 33-43.
8. The method of claim 7 , wherein the antibody agent is formulated for administration by a route selected from the group consisting of oral, intravenous, intramuscular, intra-arterial, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical, mucosal, nasal, buccal, enteral, sublingual, intratracheal or bronchial.
9. The method of claim 8 , wherein the administration is by intratracheal or bronchial instillation.
10. The method of claim 8 , wherein the administration is by inhalation.
11. The method of claim 7 , wherein the antibody agent is formulated as an oral spray, a nasal spray, or an aerosol.
12. A method of treating a subject suffering from or susceptible to influenza infection by administering the composition of claim 1 .
13. A method of detecting a hemagglutinin (HA) polypeptide in a sample by contacting a sample with the composition of claim 1 .
14. The method of claim 13 , wherein the sample is or comprises one or more of blood, serum/plasma, peripheral blood mononuclear cells/peripheral blood lymphocytes (PBMC/PBL), sputum, urine, feces, throat swabs, dermal lesion swabs, cerebrospinal fluids, cervical smears, pus samples, food matrices, and tissues from various parts of the body such as brain, spleen, and liver.
15. The method of claim 13 , wherein the sample is an environmental sample.
16. The method of claim 15 , wherein the environmental sample is or comprises one or more of soil, water and flora.